Reviewing Teleflex (NYSE:TFX) & Enovis (NYSE:ENOV)

Teleflex (NYSE:TFX) and Enovis (NYSE:ENOV) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership.

Risk & Volatility

Teleflex has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Comparatively, Enovis has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500.

Insider and Institutional Ownership

95.6% of Teleflex shares are held by institutional investors. Comparatively, 98.5% of Enovis shares are held by institutional investors. 0.7% of Teleflex shares are held by company insiders. Comparatively, 2.9% of Enovis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Teleflex and Enovis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Teleflex	-39.67%	11.93%	5.44%
Enovis	-47.96%	12.03%	4.91%

Valuation and Earnings

This table compares Teleflex and Enovis”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teleflex	$1.99 billion	2.65	-$905.64 million	($23.29)	-5.35
Enovis	$2.25 billion	0.46	-$1.18 billion	($19.26)	-0.94

Teleflex has higher earnings, but lower revenue than Enovis. Teleflex is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Teleflex and Enovis, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teleflex	1	6	4	1	2.42
Enovis	1	1	10	0	2.75

Teleflex currently has a consensus target price of $152.90, suggesting a potential upside of 22.82%. Enovis has a consensus target price of $40.38, suggesting a potential upside of 123.94%. Given Enovis’ stronger consensus rating and higher possible upside, analysts plainly believe Enovis is more favorable than Teleflex.

Summary

Enovis beats Teleflex on 10 of the 15 factors compared between the two stocks.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.